Exelixis
EXEL
#2109
Rank
S$9.81 B
Marketcap
$34.41
Share price
-1.53%
Change (1 day)
17.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : S$0.85 B

According to Exelixis's latest financial reports the company's total liabilities are S$0.85 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31S$0.89 B14.63%
2022-12-31S$0.78 B42.89%
2021-12-31S$0.54 B60.24%
2020-12-31S$0.34 B27.12%
2019-12-31S$0.26 B46.2%
2018-12-31S$0.18 B-62.92%
2017-12-31S$0.49 B-32.42%
2016-12-31S$0.73 B9.41%
2015-12-31S$0.66 B15.73%
2014-12-31S$0.57 B4.52%
2013-12-31S$0.55 B6.57%
2012-12-31S$0.51 B32.59%
2011-12-31S$0.39 B-48.38%
2010-12-31S$0.75 B6.53%
2009-12-31S$0.71 B8.24%
2008-12-31S$0.65 B39.43%
2007-12-31S$0.47 B1.04%
2006-12-31S$0.46 B1.92%
2005-12-31S$0.45 B29.22%
2004-12-31S$0.35 B6.22%
2003-12-31S$0.33 B17.99%
2002-12-31S$0.28 B39.83%
2001-12-31S$0.20 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$73.00 B 8,477.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$79.25 B 9,212.05%๐Ÿ‡ซ๐Ÿ‡ท France
S$89.85 B 10,457.60%๐Ÿ‡บ๐Ÿ‡ธ USA
S$101.04 B 11,773.06%๐Ÿ‡บ๐Ÿ‡ธ USA
S$110.69 B 12,906.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$142.69 B 16,666.48%๐Ÿ‡บ๐Ÿ‡ธ USA
S$167.00 B 19,523.59%๐Ÿ‡บ๐Ÿ‡ธ USA
S$66.56 M-92.18%๐Ÿ‡บ๐Ÿ‡ธ USA
S$94.28 M-88.92%๐Ÿ‡บ๐Ÿ‡ธ USA